Social Behavior – Page 19

Controversy Surrounds FDA’s Fast-Track Approval of Sarepta’s Duchenne Muscular Dystrophy Gene Therapy

1 year ago talkbio0Tagged Accelerated, Advocacy, Approved, Clinical Trials, DMD, Duchenne, Effectiveness, gene therapy, Muscular Dystrophy, Muscular Dystrophy, Duchenne, Regulation of biological process, Safety, United States Food and Drug Administration

FDA, Sarepta Therapeutics, Duchenne Muscular Dystrophy (DMD), gene therapy, accelerated approval, controversy, clinical trials, efficacy, safety, patient advocacy, regulatory process.

The Closure of Walmart Health Highlights Significant Hurdles for Retail Health Innovators

1 year ago talkbio0Tagged accessibility, competition, disruptors, Engaged to be married, Health, Health care facility, innovation, Landscapes, Reparative closure, Walmart Health

Walmart Health, retail health, disruptors, challenges, closure, innovation, healthcare, accessibility, competition, patient engagement, healthcare landscape.

Editas Medicine and Bristol Myers Squibb Expand T Cell Therapy Collaboration; KalVista Pharmaceuticals Seeks Partnership for Preclinical Hereditary Angioedema Program

1 year ago talkbio0Tagged Angioedemas, Hereditary, Collaboration, Editas Medicine, KalVista, Myers, Partnership, preclinical program, squibb, T cell therapy

Editas Medicine, Bristol Myers Squibb, T cell therapy, collaboration, KalVista Pharmaceuticals, preclinical program, hereditary angioedema (HAE), partnership.

Harmony Pharmaceuticals Expands into Rare Genetic Epilepsies with Acquisition of Epygenix Therapeutics

1 year ago talkbio0Tagged Acquisition (action), CDK-like kinase inhibitors, Collaboration, development aspects, Epygenix, genetic epilepsies, Harmony Pharmaceuticals, Infantile Severe Myoclonic Epilepsy, Mutation, research

Harmony Pharmaceuticals, Epygenix Therapeutics, rare genetic epilepsies, acquisition, treatment, research, development, collaboration, genetic mutations, Dravet syndrome, CDK-like kinase inhibitors

Ono Pharmaceutical Strengthens Oncology Portfolio with Acquisition of Deciphera Pharmaceuticals for $2.4 Billion

1 year ago talkbio0Tagged Acquisition (action), cancer treatments, Clinical Development, Collaboration, Deciphera, Dosage Forms, expansion, Generalized, Market, Oncology Pipeline, strategic

Ono Pharmaceutical, Deciphera Pharmaceuticals, oncology pipeline, acquisition, $2.4 billion, cancer treatments, kinase inhibitors, strategic expansion, global market, clinical development, collaboration.